[go: up one dir, main page]

LT4045039T - Žmogaus integrino alfa4beta7 slopinimas - Google Patents

Žmogaus integrino alfa4beta7 slopinimas

Info

Publication number
LT4045039T
LT4045039T LTEPPCT/US2020/055986T LTUS2020055986T LT4045039T LT 4045039 T LT4045039 T LT 4045039T LT US2020055986 T LTUS2020055986 T LT US2020055986T LT 4045039 T LT4045039 T LT 4045039T
Authority
LT
Lithuania
Prior art keywords
inhibiting human
human integrin
integrin
inhibiting
human
Prior art date
Application number
LTEPPCT/US2020/055986T
Other languages
English (en)
Lithuanian (lt)
Inventor
Matthew G. Bursavich
Dan CUI
James E. Dowling
Kristopher N. Hahn
Bryce A. Harrison
Fu-Yang Lin
Blaise S. LIPPA
Bruce N. Rogers
Dawn M. Troast
Cheng Zhong
Kyle D. Konze
Aleksey I. Gerasyuto
Byungchan Kim
Salma RAFI
Tyler DAY
Eugene Hickey
Evelyne HOUANG
Robert Zahler
Original Assignee
Morphic Therapeutic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic, Inc. filed Critical Morphic Therapeutic, Inc.
Publication of LT4045039T publication Critical patent/LT4045039T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEPPCT/US2020/055986T 2019-10-16 2020-10-16 Žmogaus integrino alfa4beta7 slopinimas LT4045039T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
PCT/US2020/055986 WO2021076890A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α4β7

Publications (1)

Publication Number Publication Date
LT4045039T true LT4045039T (lt) 2025-08-11

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2020/055986T LT4045039T (lt) 2019-10-16 2020-10-16 Žmogaus integrino alfa4beta7 slopinimas

Country Status (36)

Country Link
US (3) US20240174632A1 (es)
EP (3) EP4045039B1 (es)
JP (7) JP7437490B2 (es)
KR (2) KR20220102669A (es)
CN (3) CN115087444B (es)
AR (1) AR120244A1 (es)
AU (2) AU2020366435A1 (es)
BR (1) BR112022007284A2 (es)
CA (1) CA3154269A1 (es)
CL (1) CL2022000959A1 (es)
CO (1) CO2022005759A2 (es)
CR (1) CR20220205A (es)
CU (1) CU20220027A7 (es)
DK (1) DK4045039T3 (es)
DO (2) DOP2022000081A (es)
EC (1) ECSP22038978A (es)
ES (1) ES3035561T3 (es)
FI (1) FI4045039T3 (es)
HR (1) HRP20250749T1 (es)
HU (1) HUE071814T2 (es)
IL (2) IL319053A (es)
LT (1) LT4045039T (es)
MA (1) MA57399B1 (es)
MD (1) MD4045039T2 (es)
MX (1) MX2022004406A (es)
PE (1) PE20221829A1 (es)
PH (1) PH12022550886A1 (es)
PL (1) PL4045039T3 (es)
PT (1) PT4045039T (es)
RS (1) RS66976B1 (es)
SI (1) SI4045039T1 (es)
TW (7) TWI775182B (es)
UA (1) UA130059C2 (es)
UY (1) UY38926A (es)
WO (3) WO2021076890A1 (es)
ZA (2) ZA202203872B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI856956B (zh) 2018-04-12 2024-10-01 美商莫菲克醫療股份有限公司 人類整合素α４β７拮抗劑
IL282545B2 (en) 2018-10-30 2025-04-01 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3139526A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
PH12022550876A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CA3152714A1 (en) 2019-10-16 2021-04-22 Pingchen Fan Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
KR20220102669A (ko) * 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제
WO2023125182A1 (zh) * 2021-12-27 2023-07-06 海思科医药集团股份有限公司 一种丙酸衍生物及其在医药上的应用
WO2024051819A1 (zh) 2022-09-09 2024-03-14 西藏海思科制药有限公司 一种丙酸衍生物及其在医药上的应用
KR20250120367A (ko) 2022-12-22 2025-08-08 신테라, 인크. 알파4 베타7 인테그린 안타고니스트 및 이의 용도
CN120957974A (zh) * 2023-02-21 2025-11-14 希四克斯探索有限公司 大环α4β7整合素抑制剂
CN121335980A (zh) 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 Sod1调节组合物及其使用方法
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796A (zh) * 2024-11-20 2025-02-25 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159450C (en) 1993-03-31 2002-01-08 Norman Anthony Abood 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
EP0932615A1 (en) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999026921A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU4584199A (en) 1998-06-29 2000-01-17 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
EP1100506A4 (en) * 1998-07-29 2002-06-26 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
BR0010349B1 (pt) 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
ATE364592T1 (de) 1999-09-24 2007-07-15 Genentech Inc Tyrosinderivate
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
IL154496A0 (en) * 2000-08-30 2003-09-17 Pharmacia Corp GEM-SUBSTITUTED alpha v beta3 INTEGRIN ANTAGONISTS
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
IL163725A0 (en) 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
HUE028441T2 (hu) 2004-09-03 2016-12-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
WO2006112951A2 (en) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
WO2006131200A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
CA3127202A1 (en) 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
AR092908A1 (es) 2012-10-05 2015-05-06 Genentech Inc Metodos para diagnosticar y tratar enfermedad intestinal inflamatoria
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3262072A1 (en) 2015-02-26 2018-01-03 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
EP3589627A4 (en) * 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. (ALPHA-V) (BETA-6) INHIBITORS INTEGRIN
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
TWI856956B (zh) * 2018-04-12 2024-10-01 美商莫菲克醫療股份有限公司 人類整合素α４β７拮抗劑
CA3115830C (en) * 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
IL282545B2 (en) 2018-10-30 2025-04-01 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
KR20220102669A (ko) 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제

Also Published As

Publication number Publication date
US11370773B1 (en) 2022-06-28
TWI900200B (zh) 2025-10-01
FI4045039T3 (fi) 2025-06-20
US11104661B1 (en) 2021-08-31
BR112022007284A2 (pt) 2022-07-05
JP2024116230A (ja) 2024-08-27
UA130059C2 (uk) 2025-10-29
PE20221829A1 (es) 2022-11-29
PH12022550886A1 (en) 2023-05-03
HRP20250749T1 (hr) 2025-08-15
DK4045039T3 (da) 2025-06-30
WO2021076890A1 (en) 2021-04-22
CA3154269A1 (en) 2021-04-22
EP4228634A1 (en) 2023-08-23
EP4045039A4 (en) 2023-12-13
CN119192137A (zh) 2024-12-27
EP4559525A3 (en) 2025-08-20
TWI802477B (zh) 2023-05-11
EP4228634A4 (en) 2024-12-18
CL2022000959A1 (es) 2023-04-28
TWI888065B (zh) 2025-06-21
RS66976B1 (sr) 2025-07-31
ZA202303992B (en) 2024-06-26
JP7437490B2 (ja) 2024-02-22
JP7437495B2 (ja) 2024-02-22
SI4045039T1 (sl) 2025-07-31
JP7209116B2 (ja) 2023-01-19
TWI840047B (zh) 2024-04-21
JP2024054293A (ja) 2024-04-16
ES3035561T3 (en) 2025-09-04
JP2022548809A (ja) 2022-11-22
WO2021076902A1 (en) 2021-04-22
JP2023036958A (ja) 2023-03-14
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
IL319053A (en) 2025-04-01
US20240174632A1 (en) 2024-05-30
AU2020366435A1 (en) 2022-04-21
MD4045039T2 (ro) 2025-11-30
DOP2025000034A (es) 2025-04-08
DOP2022000081A (es) 2022-07-31
CR20220205A (es) 2022-07-22
PT4045039T (pt) 2025-07-02
IL292296B2 (en) 2025-07-01
TWI775182B (zh) 2022-08-21
WO2022081983A1 (en) 2022-04-21
KR20220102669A (ko) 2022-07-20
EP4045039A1 (en) 2022-08-24
AU2021361031A1 (en) 2023-06-08
IL292296B1 (en) 2025-03-01
JP2024054296A (ja) 2024-04-16
JP7717202B2 (ja) 2025-08-01
IL292296A (en) 2022-06-01
KR20230088376A (ko) 2023-06-19
AR120244A1 (es) 2022-02-09
TW202126624A (zh) 2021-07-16
JP2022542184A (ja) 2022-09-29
TW202500558A (zh) 2025-01-01
JP7500785B2 (ja) 2024-06-17
TW202500559A (zh) 2025-01-01
JP2023500437A (ja) 2023-01-06
ECSP22038978A (es) 2022-06-30
HUE071814T2 (hu) 2025-09-28
ZA202203872B (en) 2024-01-31
TW202244040A (zh) 2022-11-16
MA57399B1 (fr) 2025-06-30
CO2022005759A2 (es) 2022-05-20
JP7702004B2 (ja) 2025-07-02
TW202315868A (zh) 2023-04-16
EP4045039B1 (en) 2025-04-23
CN116783161A (zh) 2023-09-19
PL4045039T3 (pl) 2025-09-15
TW202332675A (zh) 2023-08-16
EP4559525A2 (en) 2025-05-28
UY38926A (es) 2021-05-31
TWI791304B (zh) 2023-02-01
CN115087444A (zh) 2022-09-20
MX2022004406A (es) 2022-08-25
WO2021076890A4 (en) 2021-06-10
CN115087444B (zh) 2024-09-17
CU20220027A7 (es) 2022-12-12

Similar Documents

Publication Publication Date Title
ZA202303992B (en) Inhibiting human integrin alpha4beta7
SG11202101913PA (en) INHIBITING aV ß6 INTEGRIN
IL262107B (en) Overlapping bangs
GB2577220B (en) Single-ply resilient tissue products
ZA202101406B (en) Integrin antagonists
GB201706976D0 (en) Endoprosthesis
GB201801634D0 (en) #
GB201701438D0 (en) Skine tissue
GB2591218B (en) Garment
GB201907425D0 (en) WiFi security
IL287426A (en) Skin closure devices
HK40080002A (en) Inhibiting human integrin alpha4beta7
GB2588583B (en) Garment
SG11202003606SA (en) Wound-treating absorbent
GB201906969D0 (en) Tissue splayer
IL281843A (en) Transformed human erythropoietin
IL270436A (en) Sefira~m
GB201917099D0 (en) Trav triv
PT3613739T (pt) Antagonistas de integrina
GB2582777B (en) Shape-enhancing garment
GB201917205D0 (en) Use
GB201916691D0 (en) Use
GB201911427D0 (en) Garment
GB201716785D0 (en) Medicine sprays
AU2017303V (en) 'NP01' Photinia x Fraseri